Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-20
C
Catherine Ma
Researcher
Also affiliated: Winthrop Rockefeller Foundation (2025); IDEX Corporation (United States) (2017)
Unknown Researcher
1 h-index
6 pubs
2 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Catherine Ma's research focuses on understanding the progression of plasma cell disorders, particularly Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma. Her work investigates factors that predict the transformation of MGUS into more aggressive forms of myeloma. She has explored the role of polyclonal plasma cell signatures as a key indicator in this progression. Additionally, her research has examined specific risk factors for myeloma development and outcomes within the African American patient population, including the identification of a 'Low-Bone' (LB) subtype of Multiple Myeloma that is associated with poorer prognosis in this demographic.
Ma is a Co-Principal Investigator on a significant NIH-funded grant totaling $4,749,323 through the Center for Research, Health and Society, focusing on minority health and health disparities. Her collaborations at the University of Arkansas for Medical Sciences include work with Guido Tricot, David E. Mery, and Hongwei Xu, with whom she has co-authored multiple publications. Her publication record includes recent work in 2024 and 2025, indicating ongoing activity in her research areas.
Metrics
- h-index: 1
- Publications: 6
- Citations: 2
Selected Publications
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)
-
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)
-
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)
Federal Grants 1 $4,749,323 total
NIH
Co-PI
Sep 2021 - Jun 2027
Collaboration Network
Top Collaborators
Clyde Bailey
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Samer Al Hadidi
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Carolina Schinke
University of Arkansas for Medical Sciences
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Maurizio Zangari
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
John D. Shaughnessy
University of Arkansas for Medical Sciences
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Hongwei Xu
Winthrop Rockefeller Foundation
3 shared publications
In database
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Frits van Rhee
Winthrop Rockefeller Foundation
3 shared publications
In database
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
David E. Mery
Winthrop Rockefeller Foundation
3 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Guido Tricot
University of Arkansas for Medical Sciences
3 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Fumou Sun
Winthrop Rockefeller Foundation
2 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
Fenghuang Zhan
University of Arkansas for Medical Sciences
2 shared publications
In database
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- Identification of Risk Factors for Myeloma Progression in African American Patients
Yihao Zhan
Central South University (CN)
2 shared publications
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Hongling Peng
Central South University (CN)
2 shared publications
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Eric R. Siegel
University of Arkansas for Medical Sciences
2 shared publications
In database
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Similar Researchers
Based on overlapping research topics
Carolina Schinke
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Monoclonal and Polyclonal Antibodies Research
Health disparities and outcomes
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Monoclonal and Polyclonal Antibodies Research
Health disparities and outcomes
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Monoclonal and Polyclonal Antibodies Research
Cancer-related molecular mechanisms research
Manuel Heredia
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health disparities and outcomes
Cancer-related molecular mechanisms research
Guido Tricot
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health disparities and outcomes
Cancer-related molecular mechanisms research
Beverly Lyn‐Cook
National Center for Toxicological Research
Health disparities and outcomes
Cancer-related molecular mechanisms research
Disease Mechanisms Research